|
|
|
TYPE 2 DIABETES: AGGRESSIVELY MANAGING
LDL-C TO REDUCE CV RISK
Billroth Hall
|
Tuesday, 29 September 2009, 14:30 - 17:00 |
 |
| Chairman: |
Marja-Riitta Taskinen, FI
|
| 14:30 - 14:40 |
Welcome and Introduction
Marja-Riitta Taskinen, FI
|
| 14:40 - 15:10 |
Current Standards for Risk Factor Management
of the DM Patient
Adrian Brady, UK
|
| 15:10 - 15:40 |
Achieving Aggressive LDL-C targets through Blocking
Cholesterol Absorption and Inhibiting its Production
Dirk Müller-Wieland, DE
|
| 15:40 - 16:10 |
The Evidence for Ezetimibe in the Treatment
of the Diabetic Patient
Lawrence Leiter, CA
|
| 16:10 - 16:40 |
Ezetimibe: New Clinical Insights
Ronnie Willenheimer, SE
|
| 16:40 - 16:55 |
Panel Discussion and Q&A
|
| 16:55 - 17:00 |
Closing Remarks |
For further information please contact:
Corinne Gallagher
Global Academic and Professional Affairs
MSD/Schering-Plough Cholesterol Partnership
One Merck Drive
Whitehouse Station, New Jersey, 08889
USA |
| Phone: |
908-423-4799 |
| Fax: |
215-661-7984 |
| Email: |
corinne_gallagher@merck.com |
| Website: |
and |
Sponsor: MSD/Schering-Plough Pharmaceuticals
|
|
 |
|
Symposia Programme
